FDA approves once-daily tiotropium with olodaterol (Stiolto)
www.pulmccm.org
Image: Stuart Fisher The FDA approved Boehringer Ingelheim’s Stiolto, the latest of the new generation of once-daily inhalers for maintenance treatment of COPD. Stiolto contains the long-acting antimuscarinic agent tiotropium (Spiriva) and the long acting beta agonist olodaterol (marketed separately as Striverdi).
FDA approves once-daily tiotropium with olodaterol (Stiolto)
FDA approves once-daily tiotropium with…
FDA approves once-daily tiotropium with olodaterol (Stiolto)
Image: Stuart Fisher The FDA approved Boehringer Ingelheim’s Stiolto, the latest of the new generation of once-daily inhalers for maintenance treatment of COPD. Stiolto contains the long-acting antimuscarinic agent tiotropium (Spiriva) and the long acting beta agonist olodaterol (marketed separately as Striverdi).